quaratusugene ozeplasmid + osimertinib + Platinum-Based Chemotherapy
Phase 1/2Recruiting 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Carcinoma, Non-Small Cell Lung
Conditions
Carcinoma, Non-Small Cell Lung
Trial Timeline
Sep 3, 2021 → Mar 1, 2029
NCT ID
NCT04486833About quaratusugene ozeplasmid + osimertinib + Platinum-Based Chemotherapy
quaratusugene ozeplasmid + osimertinib + Platinum-Based Chemotherapy is a phase 1/2 stage product being developed by Genprex for Carcinoma, Non-Small Cell Lung. The current trial status is recruiting. This product is registered under clinical trial identifier NCT04486833. Target conditions include Carcinoma, Non-Small Cell Lung.
Hype Score Breakdown
Clinical
13
Activity
8
Company
2
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04486833 | Phase 1/2 | Recruiting |
Competing Products
20 competing products in Carcinoma, Non-Small Cell Lung